Kate Delivers Emotional Statement With William a Day After Their Serious Health Alert
'Today, on the 80th anniversary of VJ Day, we remember the courage, sacrifice, and resilience of all who served. Today we especially think of those British and Commonwealth troops who fought in the Asia-Pacific,' Kate and William, both 43, wrote in an Instagram story about the anniversary of when Japan surrendered in World War II. 'We owe an enduring debt to the generation who gave so much, and to whom we will always be grateful.'
More from StyleCaster
Serious Health Alert Issued Weeks After Kate Revealed She Still Can't 'Function Normally' Post-Cancer
Andrew's 'Nasty' Remarks About Kate May Be the Real Reason William Wants His Uncle's Title Stripped-He Was 'Rude' & 'Unkind'
The post comes a day after alerts were issued for the area where William and Kate's family lives. The U.K. Health Security Agency (UKHSA) and the Met Office have both issued an 'amber heat health alert,' due to what's being called unprecedented heat waves occurring across the UK, the BBC reported. It affects everyone who is living in the Windsor state. This includes Adelaide Cottage, where Kate Middleton and Prince William live with their kids, Prince George, Princess Charlotte, and Prince Louis.Though Kate Middleton has been in remission after her cancer diagnosis last year, the Princess of Wales has been adjusting back to normal life. recently spoke about her cancer recovery with patients and staff members of the NHS. 'You put on a sort of brave face, stoicism through treatment,' she explained, but also added that, 'Treatment's done, then it's like, 'I can crack on, get back to normal,' but actually, the phase afterwards is really, really difficult.'
'You're not necessarily under the clinical team any longer, but you're not able to function normally at home as you perhaps once used to,' she explained. 'And actually, someone to help talk you through that, show you, and guide you through that sort of phase that comes after treatment, I think is really valuable.'
RadarOnline.com also recently reported that there has been growing concern about the future Queen's weight. 'Kate is painfully thin, and people are worried it's a sign that she is struggling with her recovery from cancer treatment – or worse, she's had a relapse,' an insider told the outlet.
Best of StyleCaster
The 26 Best Romantic Comedies to Watch if You Want to Know What Love Feels Like
These 'Bachelor' Secrets & Rules Prove What Happens Behind the Scenes Is So Much Juicier
BTS's 7 Members Were Discovered in the Most Unconventional Ways
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
38 minutes ago
- Medscape
Risk for VTE Elevated in Rheumatoid Arthritis
TOPLINE: Patients with rheumatoid arthritis (RA) had a 46% higher risk for venous thromboembolism (VTE) than matched control individuals, with an elevated risk persisting across all age groups, BMI categories, and disease durations. METHODOLOGY: Researchers conducted a matched cohort study to assess the risk for VTE in individuals with RA and to examine how the risk varied according to demographic and clinical factors. They included 23,410 patients with RA (mean age, 59.0 years; 71.1% women; mean BMI, 27.1) having no history of VTE and 93,640 matched control individuals who were registered with a UK general practice between 1999 and 2018. The primary outcome was the diagnosis of VTE, including deep venous thrombosis and pulmonary embolism as composite outcomes, using diagnostic codes, with an average follow-up duration of 8.2 years. TAKEAWAY: Overall, 845 and 2020 VTE events were noted in patients with RA and matched control individuals, respectively. Patients with RA had a higher risk for VTE than matched control individuals (adjusted hazard ratio [aHR], 1.46; P < .001), with a higher relative excess risk seen in both men (aHR, 1.62; P < .001) and women (aHR, 1.52; P < .001). Younger patients aged 18-49 years with RA had the highest relative excess risk for VTE (aHR, 2.13) compared with those aged 50-69 years (aHR, 1.57) and those aged 70 years or older (aHR, 1.34; P < .001 for all). Compared with matched control individuals, the relative excess risk for VTE was highest among patients with RA having normal BMI (< 25; aHR, 1.66 vs 1.60 for those having BMI 25-30 and 1.41 for those having BMI > 30; P < .001 for all). The risk for VTE remained elevated regardless of disease duration. IN PRACTICE: "The excess risk of VTE is apparent within 2 years of disease onset, and is relatively more marked among younger individuals with RA when compared with individuals without RA. This has important clinical implications, and highlights the need to consider VTE risk in all patients diagnosed with RA," the authors wrote. SOURCE: This study was led by Mark D. Russell, Centre for Rheumatic Diseases, King's College London, London, England. It was published online on August 07, 2025, in Rheumatology. LIMITATIONS: This study utilised routinely collected data from primary care in the UK, potentially limiting generalisability. Data on disease activity and inflammation burden were not available, and data on immunosuppressant medications were only from primary care prescriptions. Unmeasured confounding and diagnostic misclassification related to the reliance on routinely collected healthcare data may have existed. DISCLOSURES: This study was sponsored by Pfizer, with some authors being current or former employees of Pfizer. Several authors reported having financial relationships with various pharmaceutical companies, including Pfizer, AbbVie, Galapagos, and Johnson & Johnson. One author reported being a co-editor for Rheumatology but has not peer reviewed or made any editorial decisions related to this study. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
38 minutes ago
- Medscape
Elevated FIT Result Ups All-Cause and Non-CRC Mortality Risk
TOPLINE: In an English cohort study, patients with symptomatic presentation of colorectal cancer (CRC) and faecal immunochemical test (FIT) results ≥ 10 µg of haemoglobin (Hb)/g had a higher risk for 1-year all-cause and non-CRC mortality than those with FIT results < 10 μg of Hb/g. METHODOLOGY: Researchers conducted a retrospective study of a cohort of 49,889 adults with symptoms of CRC who underwent a FIT at Nottingham University Hospitals from November 2017 to November 2022. Of those included, 10,352 had a FIT result ≥ 10 μg of Hb/g (median age, 72 years; 52.5% women; 75.1% White) and 39,537 had a FIT result < 10 μg of Hb/g (median age, 63 years; 56.9% women; 67.8% White). Primary outcomes were all-cause and non-CRC mortality, with follow-up censoring at either death or 1 year after FIT. TAKEAWAY: In the year following symptomatic FIT, mortality rates were significantly higher in patients with FIT results ≥ 10 μg of Hb/g than in those with FIT results < 10 μg of Hb/g (8.3% vs 2.8%); the rate of non-CRC deaths was 92.4%. The rate of all-cause mortality was higher among patients with higher FIT results than among those with lower FIT results (87.21 vs 28.41 per 1000 person-years). Similar outcomes were observed for non-CRC deaths (74.79 vs 27.72 per 1000 person-years). After adjusting for age, sex, and year, patients with FIT results ≥ 10 μg of Hb/g had a higher risk for all-cause mortality (adjusted hazard ratio [aHR], 1.96) and non-CRC mortality (aHR, 1.70; P < .0001 for both) than those with FIT results < 10 μg of Hb/g. Standardised mortality ratios for patients with FIT results ≥ 10 μg of Hb/g were higher for both all-cause mortality (2.12) and non-CRC deaths (1.86). IN PRACTICE: "We found in our regional study in England that patients undergoing FIT for investigation of symptoms were at increased risk of mortality at 1 year following the test, and mortality was highest among those with FIT results of 10 µg of haemoglobin per g or higher," the authors wrote. "Both the risks of all-cause and non-colorectal cancer deaths were increased, and the relative risks were even greater among younger and female patients who were tested," they added. SOURCE: This study was led by Francesca L. Malcolm, MSc, School of Medicine, University of Nottingham, Nottingham, England. It was published online on August 08, 2025, in The Lancet Primary Care. LIMITATIONS: A large proportion of ethnicity data were missing, potentially affecting the generalisability of the results. The researchers were unable to examine outcomes for individuals who did not return their FITs. Potential biases existed due to misclassification and residual confounding from unmeasured factors like comorbidity, colonoscopy results, and use of antiplatelets or anticoagulants. DISCLOSURES: This study did not receive any specific funding. Malcolm received funding through a National Institute for Health and Social Care Doctoral Fellowship when manuscript revisions were carried out. Three authors reported receiving grant funding from the UK National Institute for Health and Care Research. Additional disclosures are listed in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
38 minutes ago
- Medscape
Flu Shot Cuts Infection Risk in UK Healthcare Workers
TOPLINE: Among UK healthcare workers, seasonal flu vaccination substantially lowered the risk for infection during the winter of 2023-2024, and vaccinated staff recorded fewer positive influenza tests than their unvaccinated peers. METHODOLOGY: Researchers in England conducted a prospective cohort study to determine the vaccine effectiveness against influenza infection in 4934 UK healthcare workers (median age, 55 years; 78.7% women; 85.6% White) between September 2023 and March 2024. Participants submitted respiratory swabs for influenza testing and completed online questionnaires every fortnight; status of seasonal influenza vaccination was confirmed via follow-up questionnaires and linked national registry data. The primary outcome was polymerase chain reaction (PCR)-positive influenza infection; the secondary outcome was symptomatic influenza infection within 7 days before or after the PCR-positive sampling date. The median follow-up duration per participant was 156 days. TAKEAWAY: Overall, 78.2% of participants received influenza vaccination, of whom 5.4% tested positive for influenza, with 4.6% among those tested at least 14 days after vaccination and 8.1% among those unvaccinated or tested fewer than 14 days after vaccination. Vaccine effectiveness was 39.9% (95% CI, 21.8-53.8) against all influenza infections and 38.7% (95% CI, 18.4-53.9) against symptomatic cases, with similar effectiveness observed for both case-control and test-negative case-control analyses. Vaccinated participants were more likely to be aged 65 years or older (8.7% vs 3.8%), men (22.6% vs 16.9%), and White (87.4% vs 79.1%) and have a chronic disease or immunosuppression (28.7% vs 20.7%) than unvaccinated participants. IN PRACTICE: "The findings of this study, the largest to our knowledge to estimate influenza VE [vaccine effectiveness] in HCWs [healthcare workers], emphasise the ongoing importance of routine seasonal influenza vaccination of this occupational group," the authors wrote. "Efforts to increase influenza vaccine uptake in HCWs are likely to require a multifaceted approach that includes a focus on supply of and access to vaccines, as well as educational approaches to address existing concerns," they added. SOURCE: This study was led by Luke J. McGeoch, Field Service South-East and London, Chief Medical Advisor's Group and Field Epidemiology Training Programme of the UK Health Security Agency, London, England. It was published online on August 12, 2025, in Journal of Infection. LIMITATIONS: The 14-day interval between successive swabs may have resulted in missed infections that arose and cleared between tests. Vaccine effectiveness by influenza types and subtypes could not be assessed due to unavailable data, and the study had limited statistical power for subgroup analyses. DISCLOSURES: This study was supported by the UK Health Security Agency and the UK Department of Health and Social Care, with contributions from governments of Northern Ireland, Scotland, and Wales; the National Institute for Health Research; UK Research and Innovation's UK Medical Research Council; and others. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
